COMPANY

ImCare Biotech

HQ: Doylestown, PA source · imcarebiotech.com ↗ · Mid-Atlantic

Location: Doylestown, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: hepatocellular carcinoma Hepatic Cancer cholangiocarcinoma

1Trials (company is sponsor)9NIH grants

Timeline

2025-08 Trial start —: Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis source ↗
Jun 20, 2025 Grant Government grant — SBIR: $364,763 (annual award, as published), announced Jun 20, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Upcoming milestones

2028-08 (ESTIMATED) · · Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis · NCT06994130

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jun 20, 2025 Government grant — SBIR: $364,763 (annual award, as published), announced Jun 20, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06994130	Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis	Not listed	Not yet recruiting	2025-08	2028-08 (estimated)

NIH awards 9

Annual award amounts. Total $6.4M.

Aug 28, 2023 NIH award 5R44CA165314-07 FY2023: $1,289,036 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic Kit for Hepatocellular C source ↗
Jul 25, 2022 NIH award 5R44CA165314-06 FY2022: $1,283,792 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic Kit for Hepatocellular C source ↗
Sep 17, 2021 NIH award 2R44CA165314-05A1 FY2021: $1,420,847 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic Kit for Hepatocellular source ↗
Mar 25, 2021 NIH award 2SB1CA165314-05A1 FY2021: $166,729 awarded for that fiscal year; activity SB1 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. Comprehensive Intellectual Property, Reimbu source ↗
Sep 11, 2018 NIH award 3R44CA165314-04S1 FY2018: $1,400 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic biomarker for Hepatocellul source ↗
Mar 10, 2017 NIH award 5R44CA165314-04 FY2017: $654,671 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic biomarker for Hepatocellul source ↗
Jun 24, 2016 NIH award 5R44CA165314-03 FY2016: $657,468 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic biomarker for Hepatocellul source ↗
Mar 31, 2015 NIH award 2R44CA165314-02A1 FY2015: $632,643 awarded for that fiscal year; activity R44 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic biomarker for Hepatocell source ↗
Aug 28, 2012 NIH award 1R43CA165314-01A1 FY2012: $292,459 awarded for that fiscal year; activity R43 (SBIR); PI LU, XUANYONG; recipient as written: IMCARE BIOTECH, INC., DOYLESTOWN, PA. A novel diagnostic biomarker for hepatocell source ↗